Clinical Report: Mapping Carbon Hotspots in Pharma Supply Chains

Overview

A recent study reveals that carbon emissions in pharmaceutical supply chains are influenced more by the structural position of supply chain nodes than by their individual emissions. The introduction of a responsibility contribution index (RCI) highlights the importance of targeting central players for effective decarbonization strategies.

Background

Decarbonizing pharmaceutical supply chains is critical as they represent a significant source of health-sector emissions. With increasing sustainability regulations, understanding the dynamics of emissions across supply chains can help identify effective intervention points. This study provides a framework for prioritizing decarbonization efforts based on structural influence and emission intensity.

Data Highlights

The study utilized life cycle assessment and social network analysis to evaluate emissions across supply chains for three drugs, revealing that a few central nodes significantly impact overall carbon footprints.

Key Findings

• Carbon emissions are concentrated along a few 'backbone' pathways in supply chains.
• Logistics hubs and contract manufacturers can disproportionately influence total carbon footprints.
• The responsibility contribution index (RCI) ranks supply chain nodes by emission intensity and structural influence.
• High-emission processes with limited connectivity are less impactful at the system level.
• Targeting nodes with high emissions and strong control over flows can yield significant carbon reductions.

Clinical Implications

Pharmaceutical companies should focus on central supply chain nodes for decarbonization efforts, as these can lead to greater overall reductions in carbon emissions. Implementing strategies that consider network dynamics will be essential in meeting tightening sustainability regulations.

Conclusion

The study emphasizes the need for a shift in focus from individual emission hotspots to the structural dynamics of supply chains to achieve effective decarbonization in the pharmaceutical industry.

References

1. WHO, Decarbonizing the healthcare supply chain strategic actions for health systems, 2025 -- WHO Guidelines
2. NHS England, Guidance: Desflurane decommissioning and clinical use, 2023 -- NHS Guidance
3. The Medicine Maker, The Strategic Questions Reshaping the CDMO Map, 2026 -- Industry Insights
4. Drug Safety, Barcoding Standards and Their Impact on the Traceability of Biological Medicinal Products: Challenges and Prospects, 2018 -- Research Article
5. The Analytical Scientist, Beating Biopharma Manufacturing Bottlenecks with Raman Spectroscopy, 2026 -- Analytical Insights
6. the medicine maker — Beating Biopharma Manufacturing Bottlenecks with Raman Spectroscopy
7. Decarbonizing the healthcare supply chain strategic actions for health systems
8. NHS England » Guidance: Desflurane decommissioning and clinical use
9. Carbon emissions associated with clinical trials: a scoping review - ScienceDirect